For the third quarter of 2026, analysts expect Airsculpt Technologies to report revenue of $34.36 million and an EPS loss of $0.03, with the current $1.64 stock price trading well below the average analyst target of $4.50. Investors are primarily focused on whether the company can leverage the GLP-1 medication "tailwind" to drive a rebound in skin-tightening procedure volumes.
Recent performance has been strained by high customer acquisition costs and a widening net loss in Q2, which prompted management to lower its full-year 2026 adjusted EBITDA guidance to a range of $12 million to $14 million. Additionally, markets are watching for updates on the company's debt refinancing following a recent lender-imposed deadline.